Dabigatran May Be Better of New Stroke Drugs (CME/CE)
(MedPage Today) -- The highest approved dose of dabigatran (Pradaxa) was better at reducing the risk of stroke or systemic embolism in patients with atrial fibrillation than rivaroxaban (Xarelto), an indirect comparison showed.
No comments:
Post a Comment